SEC Form 4/A · accession 0001179110-19-003411
Allergan plc · AGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
James DArecca
Officer — Chief Accounting Officer
Period of report
Mar 7, 2018
Accepted (ET)
Mar 6, 2019 · 3:48 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001578845
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares, par value $0.0001F1,F2 | Mar 7, 2018 | A | 1,826 | $153.22 | A | 5,809 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This amended Form 4 includes 130 restricted share units related to the March 7, 2018 grant, which were inadvertently omitted from the Form 4 filed by the Reporting Person on March 8, 2018. The reported securities are restricted share units, each of which represents a right to receive one ordinary share of Allergan plc. The restricted share units will vest twenty-five percent (25%) on March 7, 2019, twenty-five percent (25%) on March 7, 2020, twenty-five percent (25%) on March 7, 2021 and twenty-five percent (25%) on March 7, 2022.
- F2Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc.